1. Home
  2. Azioni
  3. Stati Uniti
  4. Nasdaq
  5. Annexon, Inc.
  6. Notizie
  7. Altre lingue
    ANNX   US03589W1027

ANNEXON, INC.

(ANNX)
  Rapporto
Tempo differito Nasdaq  -  22:00 24/06/2022
3.850 USD   -1.53%
07/06Annexon dice che il farmaco per la malattia di Huntington ha stabilizzato la progressione della malattia nello studio di Fase 2; le azioni salgono
MT
07/06Annexon, Inc. Riferisce i risultati dello studio clinico di Fase 2 che dimostrano che l'inibizione del complemento classico a monte è associata a un beneficio clinico nella malattia di Huntington’S
CI
10/05ANNEXON, INC.: HC Wainwright ottimista sul caso
MM
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su ANNEXON, INC.
24/06ANNEXON, INC.(NASDAQGS: ANNX) dropped from Russell Small Cap Comp Value Index
24/06ANNEXON, INC.(NASDAQGS: ANNX) dropped from Russell 3000E Index
24/06ANNEXON, INC.(NASDAQGS: ANNX) dropped from Russell 2500 Index
24/06ANNEXON, INC.(NASDAQGS: ANNX) dropped from Russell 2500 Value Index
24/06ANNEXON, INC.(NASDAQGS: ANNX) dropped from Russell 3000E Value Index
24/06ANNEXON, INC.(NASDAQGS: ANNX) dropped from Russell 2000 Dynamic Index
24/06ANNEXON, INC.(NASDAQGS: ANNX) dropped from Russell 2000 Index
24/06ANNEXON, INC.(NASDAQGS: ANNX) dropped from Russell 2000 Value Index
24/06ANNEXON, INC.(NASDAQGS: ANNX) dropped from Russell 3000 Value Index
24/06ANNEXON, INC.(NASDAQGS: ANNX) dropped from Russell 3000 Index
24/06ANNEXON, INC.(NASDAQGS: ANNX) dropped from Russell Small Cap Completeness Index
10/06ANNEXON, INC.: Submission of Matters to a Vote of Security Holders (form 8-K)
09/06TRANSCRIPT: Annexon, Inc. - Shareholder/Analyst Call
09/06TRANSCRIPT: Annexon, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09..
07/06ANNEXON: Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classi..
07/06ANNEXON, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
07/06TRANSCRIPT: Annexon, Inc. - Special Call
07/06Annexon Says Huntington's Disease Drug Stabilized Disease Progression in Phase 2 Trial;..
07/06Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Class..
07/06Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Class..
07/06Annexon, Inc. Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical C..
02/06Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
02/06Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
01/06Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-..
01/06Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-..
12/05TRANSCRIPT: Annexon, Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-..
09/05ANNEXON, INC. Management's Discussion and Analysis of Financial Condition and Results ..
09/05Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and R..
09/05Annexon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
05/05Annexon Biosciences to Participate in Upcoming May Investor Conferences
05/05Annexon Biosciences to Participate in Upcoming May Investor Conferences
11/04TRANSCRIPT: Annexon, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-11-2..
07/04ANNEXON: Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor,..
07/04ANNEXON, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
07/04Annexon Concludes Enrollment in Phase 2 Trial of Geographic Atrophy Drug ANX007
07/04Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor..
07/04Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor..
04/04Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Confer..
21/03ANNEXON, INC.(NASDAQGS: ANNX) dropped from S&P Biotechnology Select Industry Index
03/03Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Program..
01/03ANNEXON, INC. Management's Discussion and Analysis of Financial Condition and Results ..
01/03ANNEXON: Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Yea..
01/03ANNEXON, INC.: Results of Operations and Financial Condition (form 8-K)
01/03Annexon, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
01/03Annexon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
01/03Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Ye..
28/02Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference
22/02ANNEXON, INC.: Other Events (form 8-K)
22/02Annexon, Inc. Announces Resignation of Sanjay Keswani as Executive Vice President and C..
03/02ANNEXON, INC.: Change in Directors or Principal Officers (form 8-K)
03/02Annexon, Inc. Announces Resignation of Ricky Sun as Board Member
20/01ANNEXON: Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors - Form ..
20/01ANNEXON, INC.: Change in Directors or Principal Officers, Regulation FD Disclosure, Finan..
20/01Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors
20/01Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to Its Board of Directors
10/01ANNEXON, INC.: Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
05/01Top Midday Decliners
05/01Wall Street Set for Narrow Losses Ahead of Fed Minutes
05/01Health Care Stocks Mixed Ahead of Wednesday's Open
05/01Top Premarket Decliners
05/01Annexon Phase 2 Trial of Treatment Targeting Huntington's Disease 'Well Tolerated' But ..
04/01TRANSCRIPT: Annexon, Inc. - Special Call
04/01ANNEXON, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
04/01Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clini..
04/01Annexon, Inc. Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Me..
04/01Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021ANNEXON, INC.(NASDAQGS: ANNX) added to S&P Biotechnology Select Industry Index
2021Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of C..
2021Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of C..
2021Annexon Shares Jump After HC Wainwright Initiates Coverage With Buy Recommendation
2021Annexon Shares Rise After HC Wainwright Begins Coverage at Buy
2021Graphite Bio, Inc. and Annexon, Inc. Enters into A Sublease Agreement for Office and La..
2021Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter..
2021ANNEXON, INC. Management's Discussion and Analysis of Financial Condition and Results ..
2021Annexon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
1  2  3Succ.